The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Rapid Reversal of the Diabetic Endothelial Dysfunction by Pharmacological Inhibition of Poly(ADP-Ribose) Polymerase
Abstract
Oxygen- and nitrogen-derived free radicals and oxidants play an important role in the pathogenesis of diabetic endothelial dysfunction. Recently we proposed the importance of oxidant-induced DNA strand breakage and activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) in the pathogenesis of diabetic endothelial dysfunction. In this study, we tested whether established diabetic endothelial dysfunction is reversible by PARP inhibition. The novel PARP inhibitor PJ34 (10 mg/kg per day PO) was given at various lengths (4 weeks or 3 days) for established streptozotocin-diabetic animals. In addition, we also tested whether incubation of the aortic rings with PJ34 (3 μmol/L) or a variety of other PARP inhibitors for 1 hour affects the diabetic vascular changes. Both 4-week and 3-day PARP-inhibitor treatment of streptozotocin-diabetic mice with established endothelial dysfunction fully reversed the acetylcholine-induced endothelium-dependent relaxations in vitro. Furthermore, 1-hour in vitro incubation of aortae from streptozotocin-diabetic mice with various PARP inhibitors was able to reverse the endothelial dysfunction. ATP, NAD + , and NADPH levels were markedly reduced in diabetic animals, and PARP-inhibitor treatment was able to restore these alterations. Unexpectedly, pharmacological inhibition of PARP not only prevents the development of the endothelial dysfunction but is also able to rapidly reverse it. Thus, PARP activation and the associated metabolic compromise represent an ongoing process in diabetic blood vessels. Pharmacological inhibition of this process is able to reverse diabetic endothelial dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S.-I., Matsumura, T., Kaneda, Y., Yorek, M. A., Beebe, D., Oates, P. J., Hammes, H.-P., et al. (2000) · Nature · doi:10.1038/35008121 · Cited by 4,277
Cited by
Nitric Oxide and Peroxynitrite in Health and Disease
Pacher, P., Beckman, J. S., & Liaudet, L. (2007) · Physiological Reviews · doi:10.1152/physrev.00029.2006 · Cited by 6,390
Self-citationThe Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors
Virág, L., & Szabó, C. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.3.375 · Cited by 1,373
Molecular Understanding of Hyperglycemia's Adverse Effects for Diabetic Complications
Sheetz, M. J. (2002) · JAMA · doi:10.1001/jama.288.20.2579 · Cited by 1,002
The Role of Advanced Glycation End Products in Progression and Complications of Diabetes
Goh, S.-Y., & Cooper, M. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1817 · Cited by 987
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors
Jagtap, P., & Szabó, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1718 · Cited by 896
Du, X., Matsumura, T., Edelstein, D., Rossetti, L., Zsengellér, Z., Szabó, C., & Brownlee, M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18127 · Cited by 832
Goette, A., Kalman, J. M., Aguinaga, L., Akar, J., Cabrera, J. A., Chen, S. A., Chugh, S. S., Corradi, D., D’Avila, A., Dobrev, D., et al. (2017) · Heart Rhythm · doi:10.1016/j.hrthm.2016.05.028 · Cited by 771
Vascular endothelial growth factor in eye disease
Penn, J. S., Madan, A., Caldwell, R. B., Bartoli, M., Caldwell, R. W., & Hartnett, M. E. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.001 · Cited by 762
Goette, A., Kalman, J. M., Aguinaga, L., Akar, J., Cabrera, J. A., Chen, S. A., Chugh, S. S., Corradi, D., D'Avila, A., Dobrev, D., et al. (2016) · Europace · doi:10.1093/europace/euw161 · Cited by 762
Ceriello, A. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1589 · Cited by 734
Molecular Biology of Atherosclerosis
Hopkins, P. N. (2013) · Physiological Reviews · doi:10.1152/physrev.00004.2012 · Cited by 459
Hassa, P. O., & Hottiger, M. O. (2002) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/s00018-002-8527-2 · Cited by 427
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
Curtin, N. J., & Szabo, C. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.01.006 · Cited by 369
Hyperglycemia and the Pathobiology of Diabetic Complications
Aronson, D. (2008) · Advances In Cardiology · doi:10.1159/000115118 · Cited by 362
Diabetic cardiomyopathy: mechanisms, diagnosis and treatment
HAYAT, S. A., PATEL, B., KHATTAR, R. S., & MALIK, R. A. (2004) · Clinical Science · doi:10.1042/cs20040057 · Cited by 352
Pacher, P., Obrosova, I., Mabley, J., & Szabo, C. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867053363207 · Cited by 330
Self-citationDiabetes and Advanced Glycoxidation End Products
Huebschmann, A. G., Regensteiner, J. G., Vlassara, H., & Reusch, J. E. B. (2006) · Diabetes Care · doi:10.2337/dc05-2096 · Cited by 330
Alp, N. J., Mussa, S., Khoo, J., Cai, S., Guzik, T., Jefferson, A., Goh, N., Rockett, K. A., & Channon, K. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17786 · Cited by 321
Pacher, P., & Szabó, C. (2007) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2007.00018.x · Cited by 316
Self-citationCaldwell, R. B., Bartoli, M., Behzadian, M. A., El‐Remessy, A. E. B., Al‐Shabrawey, M., Platt, D. H., & Caldwell, R. W. (2003) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.415 · Cited by 293
Varga, Z. V., Giricz, Z., Liaudet, L., Haskó, G., Ferdinandy, P., & Pacher, P. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.030 · Cited by 286
Self-citationPacher, P., Liaudet, L., Soriano, F. G., Mabley, J. G., Szabó, E., & Szabó, C. (2002) · Diabetes · doi:10.2337/diabetes.51.2.514 · Cited by 281
Self-citationRole of nitrosative stress in the pathogenesis of diabetic vascular dysfunction
Szabo, C. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00086.x · Cited by 165
“PARP-deficient mice are also resistant against the development of diabetic endothelial dysfunction (Garcia Soriano et al., 2001; Soriano et al., 2001; Pacher et al., 2002; Szabo et al., 2006a).”
BackgroundMathews, M. T., & Berk, B. C. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.156406 · Cited by 120
Fan, L., Cacicedo, J. M., & Ido, Y. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13303 · Cited by 86
Metadata
- Authors
- Soriano, F. G., Pacher, P., Mabley, J., Liaudet, L., & Szabó, C.
- Venue
- Circulation Research
- Published
- 2001-10-12
- Volume
- 89
- Issue
- 8
- Pages
- 684-691
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2116743333
- Cited by
- 190
- References
- 1
- FWCI
- 8.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.